Urol. praxi. 2025;26(1):17-22 | DOI: 10.36290/uro.2025.018

Oncological aspects of urolithiasis

doc. MUDr. Jozef Marenčák, PhD.
Bratislava

Urolithiasis is a complex multifactorial disease resulting from interactions between genetic and environmental factors as well as multiple disease states. The debate about whether urinary calculi induce subsequent malignant changes has continued without a consistent conclusion for several decades. Earlier diagnosis of urolithiasis and its appropriate management can prevent/provide a longer time period for the stones to cause chronic irritation of the local environment or for potentially harmful substances dissolved in the urine to apply their carcinogenic effect. The article clearly deals with current knowledge, opinions and hypotheses in the issue of a possible oncological link between urolithiasis and some urological malignancies. Further studies are needed to clarify the causal relationship and the carcinogenic mechanisms involved. Unequivocal recommendations for clinical practice are still insufficient.

Keywords: urolithiasis, urological tumors, possible common pathophysiology, risk factors, importance for clinical practice.

Accepted: March 10, 2025; Published: March 24, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marenčák J. Oncological aspects of urolithiasis. Urol. praxi. 2025;26(1):17-22. doi: 10.36290/uro.2025.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 24.3.2026

    References

    1. Skolarikos A, Jung H, Neisius A, et al. EAU guidelines on urolithiasis. [Internet]. [cited 2024 July 14]. Available from: https://uroweb.org/guidelines.
    2. Scales C, Smith A, Hanley J, et al. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-165. Go to original source... Go to PubMed...
    3. Cheungpasitporn W, Thongprayoon C, O´Corragain O, et al. The risk of kidney cancer with patients with kidney stones: a systematic review and meta-analysis. QJM. 2015;108(3): 205-212. Go to original source... Go to PubMed...
    4. Chow W, Lindblad P, Gridley G, et al. Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst. 1997;89(19):1453-1457. Go to original source... Go to PubMed...
    5. Shih C, Chen Y, Ou S, et al. Urinary calculi and risk of cancer: a nationwide population-based study. Medicine (Baltimore). 2014;93(29):e342. Go to original source... Go to PubMed...
    6. Van de Pol J, van den Brandt P, et al. Kidney stones and the risk of renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands cohort study. Br J Cancer. 2019;120(3):368-374. Go to original source... Go to PubMed...
    7. Warli S, Mantiri B, Sihombing B, et al. Nephrolithiasis - associated renal cell carcinoma in patients who underwent nephrectomy: a single center experience. World J Oncol. 2023;14(1):94-100. Go to original source... Go to PubMed...
    8. Yu Z, Yue W, Jiuzhi L, et al. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. Urolithiasis. 2018;46(6):573-579. Go to original source... Go to PubMed...
    9. Seggard K, Veres K, Norgaard M, et al. Pyelonephritis in persons after age 50 as a clinical marker of urogenital cancer. Clin Microbiol Infect. 2019;25(1):87-91. Go to original source... Go to PubMed...
    10. Lin C, Huang W, Fan W, et al. Associations between interventions for urolithiasis and urinary tract cancer among patients in Taiwan. Medicine. 2016;95:49:e5594. Go to original source... Go to PubMed...
    11. Mihalopoulos M, Yaghoubian A, Razdan S, et al. Understanding thelink between kidney stones and cancers of the upper urinary tract and bladder. Am J Clin Exp Urol. 2022;10(5):277-298.
    12. Raghavendran M, Rastogi A, Dubey D, et al. Stones associated renal pelvic malignancies. Indian J Cancer. 2003;40(3):108-112. Go to original source...
    13. Peerapen P, Boonmark W, Putpeerawit P, et al. Calcium oxalate crystals trigger epithelial - mesenchymal transition and carcinogenic features in renal cells: a crossroad bet­ween kidney stone disease and renal cancer. Exp Hematol Oncol. 2022;11:62. Go to original source... Go to PubMed...
    14. Shabani F, Farasat A, Mahdavi M, et al. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res. 2018;67(10):801-812. Go to original source... Go to PubMed...
    15. Hu H, Chen D, Wang Y, et al. New insights into TGB-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018;292:76-83. Go to original source... Go to PubMed...
    16. Magers M, Kaimakliotis H, Barboza M, et al. Clinico-pathological characteristics ofypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. J Clin Pathol. 2019;72(8):550-553. Go to original source... Go to PubMed...
    17. Bayraktar E, Igci M, Erturhan S, et al. Reduced gene expression of bikunin as a prognostic marker for renal cell carcinoma. Exp Oncol. 2014;36(2):107-111.
    18. Blaj V, Li M, Ho S, et al. Design of drug-like hepsin inhibitors against prostate cancer and kidney stones. Acta Pharm Sin B. 2020;10(7):1309-1320. Go to original source... Go to PubMed...
    19. Lu L, Cole A, Huang D, et al. Clinical significance of hepsin and underlying pathways in prostate cancer. Biomolecules. 2022;12(2):203. Go to original source... Go to PubMed...
    20. Damalanka V, Han Z, Karmakar P, et al. Discovery of selective matriptase and hepsin serine protease inhibitors: useful chemical tools for cancer and cell biology. J Med Chem. 2019;62(2):480-490. Go to original source... Go to PubMed...
    21. Schaeffer C, Devuyst O, Rampoldi L. Uromodulin: roles in health and disease. Annu Rev Physiol. 2021;83:477-501. Go to original source... Go to PubMed...
    22. Michaels E, Grosh L, Nakagawa Y, et al. Immunohistochemical localization of nephrocalcin, a kidney-specific glycoprotein, to renal cell carcinoma. Urology. 1988;52(5):920-924. Go to original source... Go to PubMed...
    23. Nakagawa Y. Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. Keio J Med. 1997;46(1):1-9. Go to original source... Go to PubMed...
    24. Nie M, Bal M, Yang Z, et al. Mucin-1 increases renal TRPV5 activity in vitro, and urinary levels associates with calcium nephrolithiasis in patients. J Am Soc Nephrol. 2016;27(11): 3447-3458. Go to original source... Go to PubMed...
    25. Yu L, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associa­ted MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007;282(1):773-781. Go to original source... Go to PubMed...
    26. Mao W, Wang K, Wu Z, et al. Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular. J Exp Clin Cancer Res. 2021;40(1):305. Go to original source... Go to PubMed...
    27. Wang L, Yang G, Zhao D, et al. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote Mir-19b-3p. Mol Cancer. 2019;18(1):86. Go to original source... Go to PubMed...
    28. Singhto N, Kanlaya R, Nilnumkhum A, et al. Roles of macrophage exosomes in immune response to calcium oxalate monohydrate crystals. Fron Immunol. 2018;9:316. Go to original source... Go to PubMed...
    29. Wang Q, Sun Y, Yang Y, et al. Quantitative proteomic analysis of urinary exosomes in kidney stones patients. Transl Androl Urol. 2020;9(4):1572-1584. Go to original source... Go to PubMed...
    30. Hemminki K, Hemminki O, Főrsti A, et al. Familial risks between urolithiasis and cancer. Sci Rep. 2018;8(1):3083. Go to original source... Go to PubMed...
    31. Goldfarb D, Avery A, Beara-Lasic R, et al. A twin study of genetic influences on nephrolithiasis in women and men. Kidney Int Rep. 2018;4(4):535-540. Go to original source... Go to PubMed...
    32. Hemminki K, Hemminki O, Főrsti A, et al. Familial risks in urolithiasis in the population of Sweden. BJU Int. 2018;121(3):479-485. Go to original source... Go to PubMed...
    33. Howles S, Thakker R. Genetics of kidney stone disease. Nat Rev Urol. 2020;17(7):407-421. Go to original source... Go to PubMed...
    34. Sadeghi-Bojd S, Falsafinejad F, Danesh H, et al. Macrophage migration inhibitory factor-173 G>C gene polymorphism is associated with increased risk of nephrotic syndrome in children. Iran J Kidney Dis. 2019;13:232-236.
    35. Ma G, Yuan Q, Wang Q, et al. Association between MIF-AS rs755622 and nephrolithiasis risk in Chenise population. Med Sci Monit. 2016;22:563-568. Go to original source... Go to PubMed...
    36. Sun X, Kour B, Wang X, et al. Insights into association between urolithiasis and prostate cancer. J Mens Health. 2021;17(4):52-61.
    37. Tang K, Liu H, Jiang K, et al. Predictive value of preoperative inflammatory response biomarkers for metabolic syndrome and post-PCNL systemic inflammatory response syndrome in patients with nephrolithiasis. Oncotarget. 2017;8(49):85612-85627. Go to original source... Go to PubMed...
    38. Spatola L, Ferraro P, Gambaro G, et al. Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus. Metabolism. 2018;83:225-233. Go to original source... Go to PubMed...
    39. Uzunlulu M, Telci Kaklili O, Oguz A. Association between metabolic syndrome and cancer. Ann Nutr Metab. 2016;68(3):173-179. Go to original source... Go to PubMed...
    40. Lifshitz K, Ber Y, Margel D. Role of metabolic syndrome in prostate cancer development. Eur Urol Focus. 2021;7:508-512. Go to original source... Go to PubMed...
    41. Wang F, Xu Y. Body mass index and risk of renal cancer: a dose-response meta-analysis of published cohort studies. Int J Cancer. 2014;135(7):1673-1686. Go to original source... Go to PubMed...
    42. Song X, Fan B, Ma C, et al. Clinical research on the correlations between type 2 diabetes mellitus and renal clear cell carcinoma. Zhonghua Wai Ke Za Zhi. 2013;51(7):627-630.
    43. Borghi L, Meschi T, Guerra A, et al. Essential arterial hypertension and stone disease. Kidney Int. 1999;55(6):2397-2406. Go to original source... Go to PubMed...
    44. Cupisti A, D´Alessandro C, Samoni S, et al. Nephrolithiasis and hypertension: possible links and clinical implications. J Nephrol. 2014;27(5):477-482. Go to original source... Go to PubMed...
    45. Kim C, Han K, Choi H, et al. Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study. Hypertension. 2020;75(6):1439-1446. Go to original source... Go to PubMed...
    46. Hidayat K, Du X, Zou S, et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. Go to original source... Go to PubMed...
    47. Setiawan V, Stram D, Nomura A, et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007;166(8):932-940. Go to original source... Go to PubMed...
    48. Liu C, Huang S, Wu W, et al. The impact of cigarette smoking, alcohol drinking and betel quid chewing on the risk of calcium urolithiasis. Ann Epidemiol. 2009;19(8):539-545. Go to original source... Go to PubMed...
    49. Soueidan M, Bartlett S, Noureldin Y, et al. Leisure time physical activity, smoking and risk of recent symptomatic urolithiasis: survey of stone clinic patients. Can Urol Assoc J. 2015;9(7-8):257-262. Go to original source... Go to PubMed...
    50. Sun Y, Zhou Q, Zheng J. Nephrotoxic metals of cadmium, lead, mercury and arsenic and the odds of kidney stones in adults: an exposure-response analysis of NHANES 2007-2016. Environ Int. 2019;132:105115. Go to original source... Go to PubMed...
    51. Jones P, Karim Sulaiman S, Gamage K, et al. Do lifestyle factors including smoking, alcohol, and exercise impact your risk of developing kidney stone disease? Outcomes of a systematic review. J Endourol. 2021;35(1):1-7. Go to original source... Go to PubMed...
    52. World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report. Diet, Nutrition, Physical Activity and Kidney Cancer. 2015. [Internet]. Available at: wcrf.org/kidney-cancer-2015.
    53. Zhu Y, Horikawa Y, Yang H, et al. BPDE induced lymphocytic chromosome 3p deletions may predict renal cell carcinoma risk. J Urol. 2008;179(6):2416-2421. Go to original source... Go to PubMed...
    54. Lee J, Hunter D, Spiegelman D, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst. 2007;99(10):801-810. Go to original source... Go to PubMed...
    55. Wang H, Fan J, Yu C, et al. Consumption of tea, alcohol and fruits and risk of kidney stones: a prospective cohort study in 0.5 million Chinese adults. Nutrients. 2021;13(4):1119. Go to original source... Go to PubMed...
    56. Zaitsu M, Kawachi I, Takeuchi T, et al. Alcohol consumption and risk of upper-tract urothelial cancer. Cancer Epidemiol. 2017;48:36-40. Go to original source... Go to PubMed...
    57. Witjes J, Bruins H, Carrión A, et al. EAU guidelines on muscle invasive and metastatic bladder cancer. [Internet]. [cited 2024 July 14]. Available from: https://uroweb.org/guidelines.
    58. Thongboonkert V. Roles for exosome in various kidney diseases and disorders. Fron Pharmacol. 2020;10:1655. Go to original source... Go to PubMed...
    59. Kim M, Hopfer H, Mayr M. Uric acid, kidney disease and nephrolithiasis. Ther Umsch. 2016;73(3):159-165. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.